Iterum outlines ORLYNVAH's market potential with exclusivity through 2034
Source: SeekingAlpha
2025-02-07 10:20:46 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
- Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.12 beats by $0.12
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
Read the full article on Seeking Alpha
For further details see:
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034
Iterum Therapeutics plc
NASDAQ: ITRM
ITRM Trading
1.0% G/L:
$0.1719 Last:
229,900 Volume:
$0.177 Open:
ITRM Latest News
ITRM Stock Data
$15,988,461
51,778,499
0.46%
14
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 1
